Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Celcuity Inc. (CELC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates"
03/23/2023 8-K Quarterly results
Docs: "Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
Docs: "Celcuity Inc. Balance Sheets December 31, 2021 December 31, 2020 Assets Current Assets: Cash and cash equivalents $ 84,286,381 $ 11,637,911 Deposits 22,009 22,009 Deferred transaction costs 22,144 - Payroll tax receivable 298,764 190,000 Prepaid assets 722,677 317,040 Total current assets 85,351,975 12,166,960 Property and equipment, net 312,444 558,876 Operating lease right-of-use assets 241,901 230,911 Total Assets $ 85,906,320 $ 12,956,747 Liabilities and Stockholders’ Equity: Current Liabilities: Accounts payable $ 1,507,099 $ 217,377 Finance lease liabilities 5,850 5,810 Operating lease liabilities 189,858 187,518 Accrued expenses 802,893 774,612 Total current liabilities 2,505,700 1,185,317 Finance lease liabilities 2,449 8,299 Operating lease liabilities 61,771 60,861 Note payable, ..."
11/08/2021 8-K Quarterly results
Docs: "ADDITIONAL EXHIBITS"
08/09/2021 8-K Quarterly results
Docs: "Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
05/10/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Celcuity Reports Third Quarter 2020 Financial Results and Recent Business Highlights - New clinical trial collaborations with pharmaceutical companies on track to close - - Cash burn rate steady - - Cash and cash equivalents of $13.7 million as of September 30, 2020, which is expected to support operations through 2021 - - Conference Call on Monday, November 9th at 4:30pm - Minneapolis, Minnesota—November 9, 2020—Celcuity Inc. , a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the third quarter ended September 30, 2020 and summarized recent business progress. “During the third quarter, we continued to advance our collaboration di..."
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Celcuity Reports First Quarter 2019 Financial Results Minneapolis, Minnesota—May 7, 2019—Celcuity Inc. , a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the first quarter ended March 31, 2019. Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2019, compared to the first quarter ended March 31, 2018. Celcuity reported a net loss of $1.85 million, or $0.18 per share, for the first quarter of 2019, compared to a net loss of $1.97 million, or $0.19 per share, for the first quarter of 2018. Non-GAAP adjusted net loss was $1.66 million, or $0.16 per share, for th..."
02/26/2019 8-K Quarterly results
11/13/2018 8-K Quarterly results
Docs: "Celcuity Reports Third Quarter 2018 Financial Results Minneapolis, Minnesota—November 13, 2018—Celcuity Inc. , a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the third quarter ended September 30, 2018. Unless otherwise stated, all comparisons are for the third quarter ended September 30, 2018, compared to the third quarter ended September 30, 2017. Celcuity reported a net loss of $1.9 million, or $0.18 per share, for the third quarter of 2018, compared to a net loss of $1.8 million, or $0.26 per share, for the third quarter of 2017. Net loss for the first nine months of 2018 was $5.7 mill..."
08/09/2018 8-K Quarterly results
Docs: "Celcuity Reports Second Quarter 2018 Financial Results Minneapolis, Minnesota—August 9, 2018—Celcuity Inc. , a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the second quarter ended June 30, 2018. Unless otherwise stated, all comparisons are for the second quarter ended June 30, 2018, compared to the second quarter ended June 30, 2017. Celcuity reported a net loss of $1.8 million, or $0.18 per share, for the second quarter of 2018, compared to a net loss of $1.8 million, or $0.28 per share, for the second quarter of 2017. Net loss for the first six months of 2018 was $3.8 million, or $0.37..."
05/14/2018 8-K Quarterly results
Docs: "Celcuity Reports First Quarter 2018 Financial Results Minneapolis, Minnesota—May 14, 2018—Celcuity Inc. , a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the first quarter ended March 31, 2018. Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2018, compared to the first quarter ended March 31, 2017. Celcuity reported a net loss of $2.0 million, or $0.19 per share, for the first quarter of 2018, compared to a net loss of $1.0 million, or $0.15 per share, for the first quarter of 2017. Non-GAAP adjusted net loss was $1.6 million, or $0.16 per share, for the ..."
03/15/2018 8-K Quarterly results
Docs: "Celcuity Reports Fourth Quarter and Full Year 2017 Financial Results Minneapolis, Minnesota—March 15, 2018—Celcuity Inc. a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the fourth quarter and year ended December 31, 2017. Unless otherwise stated, all comparisons are for the fourth quarter and year ended December 31, 2017, compared to the fourth quarter and year ended December 31, 2016. Celcuity reported a net loss of $1.7 million, or $0.17 per share, for the fourth quarter of 2017, compared to a net loss of $0.9 million, or $0.14 per share, for the fourth quarter of 2016. Net loss for fisc..."
11/13/2017 8-K Quarterly results
Docs: "Celcuity Reports Third Quarter Fiscal 2017 Financial Results Minneapolis, Minnesota—November 13, 2017—Celcuity Inc. a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the third quarter ended September 30, 2017. Unless otherwise stated, all comparisons are for the third quarter and nine months ended September 30, 2017, compared to the third quarter and nine months ended September 30, 2016. Celcuity reported a net loss of $1.8 million, or $0.26 per share, for the third quarter of 2017, compared to a net loss of $0.9 million, or $0.13 per share, for the third quarter of 2016. Net loss for the fi..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy